Infective endocarditis (IE) may be acquired in the community as community-acquired (CA) IE or in the healthcare setting. In Japan, cases of CA-methicillin-resistant Staphylococcus aureus (MRSA) infection as skin infection have been increasing. CA-MRSA strains, including the USA300 clone, have higher pathogenicity and are more destructive to tissue than healthcare-associated MRSA strains because of the toxins they produce, including arginine-catabolic mobile element (ACME) and Panton-Valentine leukocidin (PVL). However, only a few IE cases induced by USA300 have been reported. We herein report a 64-year-old man who developed CA-IE from a furuncle caused by USA300 MRSA producing PVL and ACME, which resulted in complications of meningitis.

Key words: USA300, PVL, ACME

(Intern Med 60: 3251-3255, 2021)
(DOI: 10.2169/internalmedicine.6902-20)

Introduction

Infective endocarditis (IE) remains a severe health problem, with an in-hospital mortality rate of about 15-20% (1). IE may be community-acquired (CA) or healthcare-associated (2). In Japan, streptococci have been a common cause of CA-IE, while staphylococci have been a common cause of healthcare-associated IE. However, the prevalence of CA-IE caused by Staphylococcus aureus has increased in recent decades, as shown in the United States and European countries (1).

The prevalence of CA-methicillin-resistant S. aureus (MRSA) skin infection has increased in Japan (3). CA-MRSA strains, including the USA300 clone, have higher pathogenicity and are more destructive to tissue than healthcare-associated MRSA strains because of the toxins they produce, including arginine-catabolic mobile element (ACME) and Panton-Valentine leukocidin (PVL) (4). However, few IE cases caused by USA300 have been reported. Acute subarachnoid hemorrhaging and septic emboli have been reported as complications of IE caused by PVL- and/or ACME- producing IE (5); however, no report has described IE caused by USA300 complicated with meningitis.

We herein report a case of CA-IE caused by USA300 MRSA producing PVL and ACME, which resulted in com-
A 64-year-old man who received mitral valve plasty due to mitral prolapse a year ago noticed an eruption on the left thigh and visited a dermatologist. The patient had no other risk factors for MRSA infection, including skin injury, recent use of antibiotics, or a history of MRSA colonization or infection. The eruption was diagnosed as a furuncle, and the pus culture from the incisional drainage was positive for MRSA. Levofloxacin (once daily 500 mg) was prescribed for 7 days, and the furuncle gradually improved.

After 25 days, he felt general fatigue, had a high fever over 39°C, and noticed another eruption on the right breast (Fig. 2A), so he took levofloxacin (once daily 500 mg). Histology of the skin showed neutrophil and lymphocyte infiltration in the dermis, indicating skin abscess (Fig. 1B). Three days later, he was rushed to our hospital by an ambulance because of a fall after losing consciousness and was admitted.

The consciousness level was improved, but he claimed nuchal pain on admission. No abnormal neurological or objective findings of the head were noted aside from a stiff neck. His blood pressure was 118/80 mmHg, pulse was 113 bpm, and body temperature was 39.3°C. A physical examination revealed a diastolic murmur (Levine III/VI) on the third left sternum border. A chest radiograph and 12-lead electrocardiogram showed no significant changes. Laboratory data showed slight leukocytosis (7,500/μL) with elevated C-reactive protein (20 mg/dL) and serum creatinine (1.1 mg/dL) levels. Lumbar puncture revealed elevated cerebrospinal fluid (CSF) levels of white blood cells (89/μL, 90% polymorphs) and CFS protein (56 g/L) with normal CSF glucose levels (78 g/dL), indicating meningitis.

Transesophageal echocardiography revealed mild aortic regurgitation, but no vegetation was detected; however transesophageal echocardiography showed an abnormal mobile structure on the left coronary cusp of the aortic valve (Fig. 2A) that was strongly suspected of being a vegetation. Blood culture revealed MRSA of the same antibiotic sensitivity profile as the previous pus culture (Table); thus, a diagnosis of IE due to furuncle complicated with meningitis was made. An antibiotic sensitivity test showed that the bacteria were sensitive to vancomycin, linezolid, and daptomycin.

Figure 1. Gross image showing a furuncle on the right breast (A) and Hematoxylin and Eosin staining of the biopsy from the furuncle showing abscess (B: arrows) with infiltration of inflammatory cells, including small lymphocytes.
zolid and daptomycin, he gradually recovered from his fever. Four weeks after the surgery, linezolid was withdrawn due to thrombocytopenia, but daptomycin was continued until six weeks after the surgery. He was discharged 39 days after admission without any disability.

**Discussion**

We reported a case of CA-IE caused by USA300 MRSA with a very high pathogenicity in a 64-year-old man who recovered after aortic valve replacement and antibiotic treatment with linezolid and daptomycin. The pathogenicity caused by the toxins produced, including ACME and PVL, resulted in complication with meningitis.

MRSA is a nosocomial pathogen in the hospital setting; however, the emergence of MRSA exhibiting high virulence in healthy individuals in the community has been reported since the late 1990s (8). CA-MRSA strains have higher pathogenicity than healthcare-associated MRSA strains because of the presence of virulence determinants and colonization factors, such as ACME and PVL (4). In Japan, *S. aureus* accounts for 21% of causes of IE, and MRSA contributes to 36% of IE cases caused by *S. aureus* (9). In cases of purulent skin soft-tissue infection, first-generation cephalosporins, amoxicillin/clavulanate, or clindamycin are recommended for empirical antibiotic treatment (10). The use of antibiotics against MRSA infection is suggested in cases at high risk of MRSA infection and those with a history of MRSA infection, a history of MRSA colonization, and failed primary treatment (10, 11). Thus, identifying the precise profile of MRSA is crucial for determining the appropriate treatment.

The USA300 clone, which is characterized as a sequence-type (ST) 8-staphylococcal cassette chromosome (SCC) *mec* type IV (ST8-IV), is a particularly virulent strain among ACME-arcA- and lukS/F-PV-positive clones and has spread rapidly in communities in the United States since it was first identified in 1999 (12).

In Japan, the number of reported IE cases provoked by USA300 is still low; however, the expected prevalence may increase in the future, as the prevalence of skin and soft tissue infection cases caused by USA300 has been increasing (13). In the US, PVL-positive USA300 clones reportedly account for 98% of skin infections of CA-MRSA (14).

The virulence of MRSA depends on the pathogen-producing genetic diversity of the accessory genome. The accessory component comprises approximately 25% of the total *S. aureus* genome. It consists of mobile genetic elements such as pathogenicity islands, bacteriophages, chromosomal cassettes, transposons, and plasmids acquired by horizontal transfer between strains (15). USA300 has multiple additional virulence determinants acquired through mobile genetic elements. Two of the most studied are ACME and PVL (16). The acquisition of ACME coding arginine...
deiminase is primarily restricted to USA300, and it precedes the rapid spread of this strain. ACME is posited to inhibit mononuclear leucocyte invasion and proliferation, leading to the suppression of the immune system and an improved survival in the low-pH environment of the skin (14, 15). Furthermore, PVL is a pore-forming toxin that targets polymorphonuclear leukocytes and macrophages. It induces cell death via necrosis or apoptosis by releasing cytotoxic lysosomal granule contents from lysed neutrophils (17). Thus, PVL-positive CA-MRSA may cause severe diseases, such as skin and soft tissue infections, necrotizing pneumonia, and bacteremia leading to IE (13). In the present case, we postulated that ACME contributed to the patient’s prolonged survival under antibiotic therapy, leading to drug resistance, and PVL contributed to the tissue-destructive effects, such as valve penetration and meningitis.

*S. aureus*-induced IE is accompanied by neurological complications, including ischemic/hemorrhagic complications and encephalitis/meningitis (18), as MRSA can adhere to and invade the blood-brain barrier through the membrane-anchored lipoteichoic acid (19). The presence of meningitis due to *S. aureus* should suggest the possibility of concomitant *S. aureus* endocarditis. IE was reportedly diagnosed in 21% of *S. aureus* meningitis cases (20). Thus, when presented with patients with meningitis caused by *S. aureus*, IE should only be ruled out through repeated echocardiography, including transesophageal echocardiography.

Although data on the treatment efficacy of meningitis caused by MRSA are insufficient, vancomycin has been the first-line therapy for MRSA bacteremia and IE for decades. It has a poor CSF penetration of approximately 5% in patients complicated with meningitis. In addition, vancomycin may become less effective when the MIC reaches 2 mg/L (21). Linezolid and daptomycin are reasonable options when vancomycin cannot be used or is ineffective. Linezolid has a good CSF penetration of approximately 66%, and daptomycin has a moderately good CSF penetration of 5% with the achievement of adequate concentrations (21). Based on previous case reports and series of patients with central nervous system infections caused by MRSA, linezolid (600

Table. Results of Drug Sensitivity from Furuncle Pus and Blood Culture.

| Antibiotics                  | MIC  | Criteria of CLSI |
|------------------------------|------|------------------|
| Penicillin G                 | >8   | R                |
| Oxacillin                    | >2   | R                |
| Ampicillin                   | >8   | R                |
| Sultamicillin                | 8    | R                |
| Ampicillin-sulbactam         | 8    | R                |
| Cefoperazon-sulbactam        | 8    | R                |
| Cefazolin                    | 2    | R                |
| Ceftazidime                  | 16   | R                |
| Ceftriaxone                  | 16   | R                |
| Cefepime                     | 4    | R                |
| Cefozopran                   | 1    | R                |
| Ciprofloxacin                | >8   | R                |
| Cefmetazole                  | 4    | R                |
| Cefaclor                     | 16   | R                |
| Flomoxef                     | 4    | R                |
| Imipenem                     | 0.25 | R                |
| Meropenem                    | 0.5  | R                |
| Cefpodoxime Proxetil         | >4   | R                |
| Gentamicin                   | <0.5 | S                |
| Arbekacin                    | <0.5 | S                |
| Erythromycin                 | >4   | R                |
| Clarithromycin               | >4   | R                |
| Clindamycin                  | <0.25| S                |
| Minocycline                  | <1   | S                |
| Vancomycin                   | 2    | S                |
| Teicoplanin                  | <0.5 | S                |
| Fosfomycin                   | <4   | S                |
| Ciprofloxacin                | >2   | R                |
| Levofloxacin                 | >4   | R                |
| Sulfamethoxazole-trimethoprim| <5   | R                |
| Rifampicin                   | <0.25| R                |
| Linezolid                    | 1    | S                |
| Azithromycin                 | >4   | R                |
| Cefdinir                     | 2    | R                |
| Piperacillin-tazobactam      | >8   | R                |
| Daptomycin                   | 0.25 | S                |

MIC: minimum inhibitory concentration, CLSI: clinical and laboratory standards institute, S: sensitive, R: resistant

Figure 3. Fiberscopic image of the aortic valve during operation, showing vegetation on the left coronary cusp (A) and perforation through the left coronary cusp (B).
The authors state that they have no Conflict of Interest (COI).

References

1. Nakatani S, Mitsutake K, Ohara T, et al. Recent picture of infective endocarditis in Japan—lessons from Cardiac Disease Registration (CADRE-IE). Circ J 77: 1558-1564, 2013.
2. Friedman ND, Kaye KS, Stout JE, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137: 791-797, 2002.
3. Yanagihara K, Araki N, Watanabe S, et al. Antimicrobial susceptibility and molecular characteristics of 857 methicillin-resistant Staphylococcus aureus isolates from 16 medical centers in Japan (2008-2009): nationwide survey of community-acquired and nosocomial MRSA. Diagn Microbiol Infect Dis 72: 253-257, 2012.
4. Yamamoto T, Nishiyama A, Takano T, et al. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. J Infect Chemother 16: 225-254, 2010.
5. Haque MS, Davis SL, Maniarski CL, et al. Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30: 72-77, 2007.
6. Nakao A, Ito T, Han X, et al. Intestinal carriage of methicillin-resistant Staphylococcus aureus in nasal MRSA carriers hospitalized in the neonatal intensive care unit. Antimicrob Resist Infect Control 3: 14, 2014.
7. Sacki M, Sato T, Furuya D, et al. Clonality investigation of clinical Escherichia coli isolates by polymerase chain reaction-based open-reading frame typing method. J Infect Chemother 26: 38-42, 2020.
8. Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev 31: 2018.
9. Hase R, Otsuka Y, Yoshida K, Hosokawa N. Profile of infective endocarditis at a tertiary-care hospital in Japan over a 14-year period: characteristics, outcome and predictors for in-hospital mortality. Int J Infect Dis 33: 62-66, 2015.
10. Kwak YG, Choi SH, Kim T, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infections. Infect Chemother 49: 301-325, 2017.
11. Watanabe S, Ohnishi T, Yuasa A, et al. The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan. J Infect Chemother 23: 503-511, 2017.
12. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 64: 441-446, 2009.
13. Takadama S, Nakaminami H, Sato A, Shoshi M, Fujii T, Noguchi N. Dissemination of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus USA300 clone in multiple hospitals in Tokyo, Japan. Clin Microbiol Infect 24: 1211.e1-1211.e17, 2018.
14. Moran GJ, Krishnasasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355: 666-674, 2006.
15. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol 17: 203-218, 2019.
16. Uhlemann AC, Dordel J, Knox JR, et al. Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community. Proc Natl Acad Sci U S A 111: 6738-6743, 2014.
17. Ozekinci T, Dal T, Yankik E, et al. Panton-Valentine leukocidin in community and hospital-acquired Staphylococcus aureus strains. Biotechnol Biotechnol Equip 28: 1089-1094, 2014.
18. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation 127: 2272-2284, 2013.
19. Sheen TR, Elbrahimi CM, Hienstra IH, Barlow SB, Peschel A, Doran KS. Penetration of the blood-brain barrier by Staphylococcus aureus: contribution of membrane-anchored lipoteichoic acid. J Mol Med (Berl) 88: 633-639, 2010.
20. Schlesinger LS, Ross SC, Sabber-D. Staphyloccocus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore) 66: 148-156, 1987.
21. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 64: e34-e65, 2017.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/).